PDL BioPharma, Inc. seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company's segments include income generating assets and product sales. The income generating assets segment consists of royalties from issued patents in the United States and elsewhere, covering the humanization of antibodies, which it refers to as the Queen et al. patents; notes and other long-term receivables, royalty rights-at fair value and equity investments. The Company's product sales segment consists of revenue derived from Tekturna, Tekturna HCT, Rasilez and Rasilez HCT (collectively, the Noden Products or Tekturna) sales. It is focused on the acquisition of additional products. As of December 31, 2016, it had a total of five notes receivable transactions outstanding and one note/royalty (hybrid) receivable transaction outstanding.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:PDLI
- CUSIP: 69329Y10
- Web: www.pdl.com
Capitalization:- Market Cap: $396.02 million
- Outstanding Shares: 160,984,000
Average Prices:- 50 Day Moving Avg: $2.42
- 200 Day Moving Avg: $2.27
- 52 Week Range: $1.93 - $3.77
P/E:- Trailing P/E Ratio: 26.15
- Foreward P/E Ratio: 14.47
- P/E Growth: 0.65
Sales & Book Value:- Annual Revenue: $103.28 million
- Price / Sales: 3.83
- Book Value: $4.65 per share
- Price / Book: 0.53
Profitability:- EBIDTA: $45.51 million
- Net Margins: 8.02%
- Return on Equity: 6.06%
- Return on Assets: 3.87%
Debt:- Debt-to-Equity Ratio: 0.15%
- Current Ratio: 1.98%
- Quick Ratio: 1.96%
Misc:- Average Volume: 1.56 million shs.
- Beta: 0.6
- Short Ratio: 9.19
Frequently Asked Questions for PDL BioPharma (NASDAQ:PDLI)
What is PDL BioPharma's stock symbol?
PDL BioPharma trades on the NASDAQ under the ticker symbol "PDLI."
How will PDL BioPharma's stock buyback program work?
PDL BioPharma declared that its Board of Directors has approved a share buyback plan on Saturday, April 8th 2017, which authorizes the company to buyback $30,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 8.6% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its stock is undervalued.
How were PDL BioPharma's earnings last quarter?
PDL BioPharma, Inc. (NASDAQ:PDLI) issued its quarterly earnings data on Wednesday, May, 3rd. The company reported $0.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.05 by $0.03. The firm had revenue of $45.44 million for the quarter. PDL BioPharma had a return on equity of 6.06% and a net margin of 8.02%. View PDL BioPharma's Earnings History.
When will PDL BioPharma make its next earnings announcement?
Where is PDL BioPharma's stock going? Where will PDL BioPharma's stock price be in 2017?
2 brokers have issued 12-month target prices for PDL BioPharma's stock. Their predictions range from $3.50 to $4.00. On average, they anticipate PDL BioPharma's stock price to reach $3.75 in the next year. View Analyst Ratings for PDL BioPharma.
What are analysts saying about PDL BioPharma stock?
Here are some recent quotes from research analysts about PDL BioPharma stock:
- 1. According to Zacks Investment Research, "PDL BioPharma reported better than expected earnings in the first quarter of 2017 whereas revenue significantly decreased year over year. The company is focused on acquiring and managing income-generating assets. PDL BioPharma has royalty agreements with several companies, whereby it has royalty rights on product sales. We are positive on the company’s recent strategic shift, whereby it is making equity investments in product-focused companies. However, the company’s dependence on revenues from royalties is not a risk-free strategy. Moreover, the company’s top line declined materially after it stopped receiving payments from certain Queen et al. patent license. The decrease in royalties from PDL's Queen et al. patents is due to the expiration of the patent license agreement with Genentech. PDL BioPharma’s shares have underperformed the Medical-Biomedical/Genetics industry in the past one year." (5/15/2017)
- 2. Cowen and Company analysts commented, "PDL reported an in-line Q1 with both total revenue ($45MM vs $43MM) and EPS." (5/3/2017)
Are investors shorting PDL BioPharma?
PDL BioPharma saw a increase in short interest during the month of June. As of June 30th, there was short interest totalling 16,311,376 shares, an increase of 13.0% from the June 15th total of 14,430,001 shares. Based on an average daily trading volume, of 1,799,346 shares, the days-to-cover ratio is presently 9.1 days. Currently, 10.4% of the company's stock are short sold.
Who are some of PDL BioPharma's key competitors?
Some companies that are related to PDL BioPharma include Arena Pharmaceuticals (ARNA), Enanta Pharmaceuticals (ENTA), TG Therapeutics (TGTX), Crispr Theraptc (CRSP), Editas Medicine (EDIT), Spectrum Pharmaceuticals (SPPI), Intellia Therapeutics (NTLA), ANI Pharmaceuticals (ANIP), Mesoblast Limited (MESO), WAVE Life Sciences (WVE), ImmunoGen (IMGN), Agenus (AGEN), Cara Therapeutics (CARA), AC Immune SA (ACIU), Inovio Pharmaceuticals (INO), Adamas Pharmaceuticals (ADMS), Abeona Therapeutics (ABEO) and Concert Pharmaceuticals (CNCE).
Who are PDL BioPharma's key executives?
PDL BioPharma's management team includes the folowing people:
- John Peter McLaughlin, President, Chief Executive Officer, Director
- Peter S. Garcia, Chief Financial Officer, Vice President
- Steffen Pietzke CPA, Chief Accounting Officer, Vice President - Finance
- Christopher Lewis Stone J.D., Vice President, General Counsel, Secretary
- Danny Hart, Vice President - Business Development
- Harold E. Selick Ph.D., Lead Independent Director
- Paul R. Edick, Independent Director
- David W. Gryska, Independent Director
- Jody S. Lindell, Independent Director
- Samuel R. Saks M.D., Independent Director
Who owns PDL BioPharma stock?
PDL BioPharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (3.00%), Bank of Montreal Can (0.24%), Eqis Capital Management Inc. (0.14%) and Aperio Group LLC (0.13%). Company insiders that own PDL BioPharma stock include Peter S Garcia and Steffen Pietzke. View Institutional Ownership Trends for PDL BioPharma.
Who sold PDL BioPharma stock? Who is selling PDL BioPharma stock?
Who bought PDL BioPharma stock? Who is buying PDL BioPharma stock?
PDL BioPharma's stock was purchased by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. Company insiders that have bought PDL BioPharma stock in the last two years include Peter S Garcia and Steffen Pietzke. View Insider Buying and Selling for PDL BioPharma.
How do I buy PDL BioPharma stock?
Shares of PDL BioPharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PDL BioPharma's stock price today?
One share of PDL BioPharma stock can currently be purchased for approximately $2.46.
MarketBeat Community Rating for PDL BioPharma (NASDAQ PDLI)MarketBeat's community ratings are surveys of what our community members think about PDL BioPharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for PDL BioPharma (NASDAQ:PDLI) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | $3.75 (52.44% upside) |
Analysts' Ratings History for PDL BioPharma (NASDAQ:PDLI)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 5/3/2017 | Cowen and Company | Reiterated Rating | Hold | | High |  |
| 12/22/2016 | Piper Jaffray Companies | Initiated Coverage | Overweight | $4.00 | N/A | |
| 2/23/2016 | Royal Bank Of Canada | Lower Price Target | Sector Perform | $5.00 -> $4.00 | N/A | |
(Data available from 7/25/2015 forward)
Earnings History for PDL BioPharma (NASDAQ:PDLI)Earnings History by Quarter for PDL BioPharma (NASDAQ PDLI)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | | | | | | | | |
| 5/3/2017 | Q1 2017 | $0.05 | $0.08 | | $45.44 million | View | Listen | |
| 11/3/2016 | Q316 | $0.08 | $0.08 | $50.69 million | $53.60 million | View | N/A | |
| 8/4/2016 | Q216 | $0.08 | $0.09 | $33.46 million | $21.00 million | View | N/A | |
| 5/4/2016 | Q116 | $0.50 | $0.52 | $142.05 million | $103.10 million | View | N/A | |
| 2/22/2016 | Q415 | $0.54 | $0.61 | $149.20 million | $178.10 million | View | Listen | |
| 11/4/2015 | Q315 | $0.61 | $0.42 | $164.80 million | $124.60 million | View | N/A | |
| 8/5/2015 | Q215 | $0.52 | $0.47 | $137.75 million | $138.10 million | View | N/A | |
| 5/6/2015 | Q115 | $0.52 | $0.50 | $140.80 million | $149.71 million | View | N/A | |
| 2/23/2015 | Q414 | $0.57 | $0.32 | $158.15 million | $117.10 million | View | Listen | |
| 11/10/2014 | Q314 | $0.56 | $0.61 | $165.10 million | $164.60 million | View | N/A | |
| 8/18/2014 | Q214 | $0.46 | $0.52 | $134.07 million | $162.80 million | View | Listen | |
| 5/12/2014 | Q114 | $0.45 | $0.44 | $130.93 million | $139.70 million | View | N/A | |
| 3/3/2014 | Q413 | $0.43 | $0.39 | $115.22 million | $110.10 million | View | N/A | |
| 11/6/2013 | Q313 | $0.37 | $0.36 | $97.09 million | $97.30 million | View | N/A | |
| 8/8/2013 | Q2 2013 | $0.54 | $0.62 | $138.20 million | $143.60 million | View | N/A | |
| 5/9/2013 | Q1 2013 | $0.35 | $0.36 | $91.69 million | $91.80 million | View | N/A | |
| 3/1/2013 | Q4 2012 | $0.31 | $0.34 | $86.08 million | $86.10 million | View | N/A | |
| 11/5/2012 | Q312 | $0.33 | $0.32 | $85.03 million | $85.20 million | View | N/A | |
| 8/2/2012 | | $0.44 | $0.52 | | | View | N/A | |
| 5/3/2012 | | $0.27 | $0.29 | | | View | N/A | |
| 2/23/2012 | | $0.28 | $0.24 | | | View | N/A | |
| 11/9/2011 | | $0.27 | $0.28 | | | View | N/A | |
| 7/27/2011 | | $0.39 | $0.39 | | | View | N/A | |
| 4/27/2011 | | $0.24 | $0.25 | | | View | N/A | |
| 2/28/2011 | | $0.21 | $0.20 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for PDL BioPharma (NASDAQ:PDLI)Current Year EPS Consensus Estimate: $0.26 EPS
Next Year EPS Consensus Estimate: $0.17 EPS
Dividend History by Quarter for PDL BioPharma (NASDAQ PDLI)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/4/2016 | quarterly | $0.05 | 6.25% | 6/2/2016 | 6/6/2016 | 6/13/2016 |
| 2/1/2016 | quarterly | $0.05 | 7.27% | 3/2/2016 | 3/4/2016 | 3/11/2016 |
| 2/2/2015 | quarterly | $0.15 | 8.22% | 6/1/2016 | 6/5/2016 | 6/12/2016 |
| 1/30/2015 | quarterly | $0.15 | 8.23% | 6/3/2015 | 6/5/2015 | 6/12/2015 |
| 1/30/2015 | quarterly | $0.15 | 8.23% | 3/3/2015 | 3/5/2015 | 3/12/2015 |
| 1/30/2015 | quarterly | $0.15 | 8.23% | 12/2/2015 | 12/4/2015 | 12/11/2015 |
| 1/30/2015 | quarterly | $0.15 | 8.23% | 9/2/2015 | 9/4/2015 | 9/11/2015 |
| 1/31/2014 | quarterly | $0.15 | 6.59% | 9/3/2014 | 9/5/2014 | 9/12/2014 |
| 1/31/2014 | quarterly | $0.15 | 6.59% | 3/3/2014 | 3/5/2014 | 3/12/2014 |
| 1/31/2014 | quarterly | $0.15 | 6.59% | 12/3/2014 | 12/5/2014 | 12/12/2014 |
| 1/31/2014 | quarterly | $0.15 | 6.59% | 6/3/2014 | 6/5/2014 | 6/12/2014 |
| 1/31/2013 | quarterly | $0.15 | 8.72% | 12/3/2013 | 12/5/2013 | 12/12/2013 |
| 1/31/2013 | quarterly | $0.15 | 8.72% | 6/3/2013 | 6/5/2013 | 6/12/2013 |
| 1/31/2013 | quarterly | $0.15 | 8.72% | 9/3/2013 | 9/5/2013 | 9/12/2013 |
| 1/30/2013 | quarterly | $0.15 | 8.72% | 3/1/2013 | 3/5/2013 | 3/12/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for PDL BioPharma (NASDAQ:PDLI)Insider Ownership Percentage: 2.20%
Institutional Ownership Percentage: 84.44%
Insider Trades by Quarter for PDL BioPharma (NASDAQ:PDLI)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/24/2017 | Peter S Garcia | VP | Buy | 25,000 | $1.98 | $49,500.00 | |
| 8/9/2016 | Peter S Garcia | VP | Buy | 10,000 | $3.00 | $30,000.00 | |
| 12/15/2015 | Peter S. Garcia | CFO | Buy | 5,000 | $3.64 | $18,200.00 | |
| 12/14/2015 | Peter S. Garcia | CFO | Buy | 10,000 | $3.42 | $34,200.00 | |
| 12/7/2015 | Steffen Pietzke | CAO | Buy | 20,590 | $3.64 | $74,947.60 | |
| 8/14/2015 | Peter S Garcia | CFO | Buy | 20,000 | $5.83 | $116,600.00 | |
| 11/26/2014 | Harold E Selick | Director | Buy | 6,000 | $8.08 | $48,480.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for PDL BioPharma (NASDAQ:PDLI)
Latest Headlines for PDL BioPharma (NASDAQ:PDLI)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to PDL BioPharma, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 7:47 PM |
| PDL BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : PDLI-US : July 21, 2017
finance.yahoo.com - July 22 at 7:29 AM |
 | PDL BioPharma, Inc. (NASDAQ:PDLI) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - July 19 at 8:00 PM |
| PDL BioPharma, Inc. (PDLI) Short Interest Up 13.0% in June
www.americanbankingnews.com - July 15 at 7:16 AM |
| ETFs with exposure to PDL BioPharma, Inc. : July 13, 2017
finance.yahoo.com - July 14 at 7:19 AM |
| PDL BioPharma, Inc. (NASDAQ:PDLI) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 11 at 12:40 PM |
| PDL BioPharma, Inc. breached its 50 day moving average in a Bearish Manner : PDLI-US : July 10, 2017
finance.yahoo.com - July 11 at 6:31 AM |
| $0.09 Earnings Per Share Expected for PDL BioPharma, Inc. (PDLI) This Quarter
www.americanbankingnews.com - July 6 at 4:24 PM |
| ETFs with exposure to PDL BioPharma, Inc. : July 3, 2017
finance.yahoo.com - July 4 at 5:51 AM |
| Short Interest in PDL BioPharma, Inc. (PDLI) Grows By 16.1%
www.americanbankingnews.com - June 28 at 7:12 AM |
| ETFs with exposure to PDL BioPharma, Inc. : June 20, 2017
finance.yahoo.com - June 21 at 1:32 AM |
| PDL BioPharma, Inc. :PDLI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 19, 2017
finance.yahoo.com - June 19 at 7:53 PM |
| PDL BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : PDLI-US : June 19, 2017
finance.yahoo.com - June 19 at 10:31 AM |
| Zacks: Analysts Anticipate PDL BioPharma, Inc. (PDLI) to Announce $0.09 Earnings Per Share
www.americanbankingnews.com - June 12 at 4:48 PM |
 | PDL BioPharma (PDLI) Presents At Jefferies 2017 Global Healthcare Conference
seekingalpha.com - June 7 at 7:02 PM |
 | Noden Pharma Notified of ANDA Filing for Tekturna® - PR Newswire - PR Newswire (press release)
www.prnewswire.com - June 6 at 8:21 AM |
| Noden Pharma Notified of ANDA Filing for Tekturna®
finance.yahoo.com - June 5 at 8:23 AM |
| ValuEngine Downgrades PDL BioPharma Inc (PDLI) to Hold
www.americanbankingnews.com - June 3 at 5:40 PM |
| PDL BioPharma to Present at the Jefferies 2017 Healthcare Conference
finance.yahoo.com - June 1 at 7:57 PM |
| PDL BioPharma: Now Is The Time To Buy - Seeking Alpha
seekingalpha.com - May 19 at 11:57 AM |
| Brokerages Expect PDL BioPharma Inc (PDLI) to Announce $0.04 EPS
www.americanbankingnews.com - May 16 at 10:46 AM |
| PDL BioPharma Inc (PDLI) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - May 15 at 12:22 PM |
| LENSAR® And PDL BioPharma Complete Strategic Financial Restructuring Of LENSAR
finance.yahoo.com - May 11 at 8:32 AM |
| PDL BioPharma Inc (PDLI) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 6 at 1:00 AM |
 | LENSAR Receives FDA Clearances for Laser Cataract Platform Integration With OCULUS Pentacam Tomographers (PDLI)
www.streetinsider.com - May 5 at 7:26 PM |
| LENSAR® Receives FDA Clearances for Laser Cataract Platform Integration With OCULUS Pentacam® Tomographers
finance.yahoo.com - May 5 at 7:26 PM |
| PDL BioPharma Inc (PDLI) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 5 at 2:30 PM |
| Edited Transcript of PDLI earnings conference call or presentation 3-May-17 8:30pm GMT
finance.yahoo.com - May 4 at 8:06 AM |
| PDL BioPharma's (PDLI) "Hold" Rating Reiterated at Cowen and Company
www.americanbankingnews.com - May 4 at 12:06 AM |
| Cowen and Company Reiterates "Hold" Rating for PDL BioPharma Inc (PDLI)
www.americanbankingnews.com - May 4 at 12:00 AM |
 | EARNINGS SUMMARY: Details of PDL BioPharma Inc. Q1 Earnings Report
www.rttnews.com - May 3 at 7:53 PM |
| Investor Network: PDL BioPharma, Inc. to Host Earnings Call
finance.yahoo.com - May 3 at 7:53 PM |
| PDL BioPharma Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 7:53 PM |
| PDL BioPharma posts 1Q profit
finance.yahoo.com - May 3 at 7:53 PM |
| PDL BioPharma (PDLI) Receives Media Impact Rating of 0.69
www.americanbankingnews.com - May 2 at 2:50 PM |
| PDL BioPharma (PDLI) Earning Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 28 at 1:01 AM |
| PDL BioPharma to Announce First Quarter 2017 Financial Results on May 3, 2017
finance.yahoo.com - April 26 at 6:05 PM |
| PDL BioPharma, Inc. – Value Analysis (NASDAQ:PDLI) : April 26, 2017
finance.yahoo.com - April 26 at 6:05 PM |
| PDL BioPharma, Inc. breached its 50 day moving average in a Bullish Manner : PDLI-US : April 25, 2017
finance.yahoo.com - April 25 at 10:21 AM |
| ETFs with exposure to PDL BioPharma, Inc. : April 24, 2017
finance.yahoo.com - April 24 at 5:52 PM |
| PDL BioPharma (PDLI) Receives Coverage Optimism Rating of 0.44
www.americanbankingnews.com - April 24 at 3:22 PM |
| PDL BioPharma Announces Settlement of Keytruda Patent Infringement Lawsuit with Merck
finance.yahoo.com - April 24 at 12:29 PM |
| PDL BioPharma to be paid $19.5 million by Merck to settle Keytruda patent suit
finance.yahoo.com - April 24 at 12:29 PM |
| PDL BioPharma (PDLI) Earning Somewhat Critical News Coverage, Study Shows
www.americanbankingnews.com - April 21 at 9:21 PM |
| PDL BioPharma (PDLI) Board of Directors Announces Stock Repurchase Plan
www.americanbankingnews.com - April 8 at 8:34 AM |
| PDL BioPharma to Hold Annual Meeting of Stockholders on June 9, 2017
finance.yahoo.com - April 7 at 11:49 AM |
| TheStreet Downgrades PDL BioPharma Inc (PDLI) to D+
www.americanbankingnews.com - April 5 at 3:16 PM |
| PDL BioPharma (PDLI) Up 5.9% Since Earnings Report: Can It Continue?
finance.yahoo.com - April 3 at 9:24 AM |
| Insider Buying: PDL BioPharma Inc (PDLI) VP Acquires 25,000 Shares of Stock
www.americanbankingnews.com - March 27 at 11:04 PM |
| PDL BioPharma (PDLI) Presents At Oppenheimer 27th Annual Healthcare Conference
seekingalpha.com - March 21 at 6:58 PM |
PDL BioPharma (PDLI) Chart for Tuesday, July, 25, 2017
